Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John P. O'Rourke is active.

Publication


Featured researches published by John P. O'Rourke.


Journal of Biological Chemistry | 1997

CCAAT/enhancer-binding protein-delta (C/EBP-delta) is induced in growth-arrested mouse mammary epithelial cells.

John P. O'Rourke; Rhonghua Yuan; Jim DeWille

CCAAT/enhancer binding proteins (C/EBPs) are a highly conserved family of DNA-binding proteins that regulate cell growth and differentiation in a highly tissue-specific manner. These experiments investigated the influence of the cell cycle on C/EBP isoform expression in mammary epithelial cells (COMMA D) and fibroblasts (NIH3T3). C/EBP-δ gene expression is induced in COMMA D cells arrested in G0 by serum and growth factor withdrawal or contact inhibition. C/EBP-δ mRNA, nuclear protein content, and DNA binding activity increase during G0 growth arrest and decrease after cell cycle induction in COMMA D cells. Growth arrest is markedly delayed in COMMA D cells expressing a C/EBP-δ antisense construct. C/EBP-β is induced during G1 of the cell cycle. In contrast to COMMA D cells, C/EBP-β and C/EBP-δ mRNA levels remain relatively constant in growth-arrested and cell cycle-induced NIH3T3 cells. However, C/EBP homologous protein (CHOP10) mRNA levels markedly increase in growth-arrested NIH3T3 cells. Both COMMA D and NIH3T3 cells express growth arrest-specific (gas1) and JunD during G0. These results demonstrate that COMMA D and NIH3T3 cells achieve a common growth arrest (G0) state by cell-specific strategies that involve the induction of different C/EBP isoforms.


Journal of Biological Chemistry | 1999

CCAAT/Enhancer-binding Protein δ Regulates Mammary Epithelial Cell G0 Growth Arrest and Apoptosis

John P. O'Rourke; Garret C. Newbound; Julie A. Hutt; Jim DeWille

CCAAT/enhancer-binding proteins (C/EBPs) are a highly conserved family of DNA-binding proteins that regulate cell-specific growth, differentiation, and apoptosis. Here, we show that induction of C/EBPδ gene expression during G0 growth arrest is a general property of mammary-derived cell lines. C/EBPδ is not induced during G0 growth arrest in 3T3 or IEC18 cells. C/EBPδ induction is G0-specific in mouse mammary epithelial cells; C/EBPδ gene expression is not induced by growth arrest in the G1, S, or G2 phase of the cell cycle. C/EBPδ antisense-expressing cells (AS1 cells) maintain elevated cyclin D1 and phosphorylated retinoblastoma protein levels and exhibit delayed G0 growth arrest and apoptosis in response to serum and growth factor withdrawal. Conversely, C/EBPδ-overexpressing cells exhibited a rapid decline in cyclin D1 and phosphorylated retinoblastoma protein levels, a rapid increase in the cyclin-dependent kinase inhibitor p27, and accelerated G0 growth arrest and apoptosis in response to serum and growth factor withdrawal. When C/EBPδ levels were rescued in AS1 cells by transfection with a C/EBPδ “sense” construct, normal G0 growth arrest and apoptosis were restored. These results demonstrate that C/EBPδ plays a key role in the regulation of G0 growth arrest and apoptosis in mammary epithelial cells.


BMC Cancer | 2011

Identification and Regulation of c-Myb Target Genes in MCF-7 Cells

Anita M. Quintana; Fan Liu; John P. O'Rourke; Scott A. Ness

BackgroundThe c-Myb transcription factor regulates differentiation and proliferation in hematopoietic cells, stem cells and epithelial cells. Although oncogenic versions of c-Myb were first associated with leukemias, over expression or rearrangement of the c-myb gene is common in several types of solid tumors, including breast cancers. Expression of the c-myb gene in human breast cancer cells is dependent on estrogen stimulation, but little is known about the activities of the c-Myb protein or what genes it regulates in estrogen-stimulated cells.MethodsWe used chromatin immunoprecipitation coupled with whole genome promoter tiling microarrays to identify endogenous c-Myb target genes in human MCF-7 breast cancer cells and characterized the activity of c-Myb at a panel of target genes during different stages of estrogen deprivation and stimulation.ResultsBy using different antibodies and different growth conditions, the c-Myb protein was found associated with over 10,000 promoters in MCF-7 cells, including many genes that encode cell cycle regulators or transcription factors and more than 60 genes that encode microRNAs. Several previously identified c-Myb target genes were identified, including CCNB1, MYC and CXCR4 and novel targets such as JUN, KLF4, NANOG and SND1. By studying a panel of these targets to validate the results, we found that estradiol stimulation triggered the association of c-Myb with promoters and that association correlated with increased target gene expression. We studied one target gene, CXCR4, in detail, showing that c-Myb associated with the CXCR4 gene promoter and activated a CXCR4 reporter gene in transfection assays.ConclusionsOur results show that c-Myb associates with a surprisingly large number of promoters in human cells. The results also suggest that estradiol stimulation leads to large-scale, genome-wide changes in c-Myb activity and subsequent changes in gene expression in human breast cancer cells.


Journal of Virology | 2002

Comparison of Gene Transfer Efficiencies and Gene Expression Levels Achieved with Equine Infectious Anemia Virus- and Human Immunodeficiency Virus Type 1-Derived Lentivirus Vectors

John P. O'Rourke; Garret C. Newbound; Donald B. Kohn; John C. Olsen; Bruce A. Bunnell

ABSTRACT This report compares gene transfer efficiencies as well as durations and levels of gene expression for human immunodeficiency virus (HIV) and equine infectious anemia virus (EIAV) lentiviral vectors in a variety of human cell types in vitro. EIAV and HIV vectors transduced equivalent numbers of proliferating and G1/S- and G2/M-arrested cells, and both had very low efficiencies of transduction into G0-arrested cells. Analysis of the levels of both the enhanced green fluorescent protein (EGFP) and mRNA demonstrated that the HIV-transduced cells expressed greater levels of EGFP protein and RNA than the EIAV-transduced cells. Measurements of vector-derived EGFP RNA half-lives were fourfold higher with the HIV vector than with the EIAV vector. Long-term culture of EIAV-transduced human cells showed a significant decrease in the number of cells expressing the transgene; however, no corresponding loss was found in EIAV-transduced equine cells. In contrast, only a moderate decrease in the number of transgene-expressing cells was seen with the HIV vectors. Taken together, these results demonstrate that the EIAV vectors transduced human cells with efficiencies similar to those of the HIV vectors. However, our data indicate that transgene expression from EIAV vectors is limited by the instability of vector-derived RNA transcripts and silencing of the EIAV vectors over time.


Oncogene | 2006

Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb.

Fan Liu; Wanli Lei; John P. O'Rourke; Scott A. Ness

The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.


Molecular and Cellular Biology | 2008

Alternative RNA Splicing Produces Multiple Forms of c-Myb with Unique Transcriptional Activities

John P. O'Rourke; Scott A. Ness

ABSTRACT The c-Myb transcription factor regulates the proliferation and differentiation of hematopoietic cells, and activated alleles of c-myb induce leukemias and lymphomas in animals. Relatively minor changes in the structure of c-Myb protein change the genes that it regulates and can unleash its latent transforming activities. Here, quantitative assays were used to analyze the alternative splicing of human c-myb transcripts. We identified an array of variant transcripts, expressed in highly regulated, lineage-specific patterns, that were formed through the use of alternate exons 8A, 9A, 9B, 10A, 13A, and 14A. Expression levels of the different splice variant transcripts were regulated independently of one another during human hematopoietic cell differentiation, and the alternative splicing of c-myb mRNAs was increased in primary leukemia samples. The alternatively spliced c-myb transcripts were associated with polysomes and encoded a series of c-Myb proteins with identical DNA binding domains but unique C-terminal domains. In several types of assays, the variant c-Myb proteins exhibited quantitative and qualitative differences in transcriptional activities and specificities. The results suggest that the human c-myb gene encodes a family of related proteins with different transcriptional activities. Enhanced alternative splicing may be a mechanism for unmasking the transforming activity of c-myb in human leukemias.


Molecular Therapy | 2003

Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors

John P. O'Rourke; K Urban; Manij Patel; John C. Olsen; Bruce A. Bunnell

Skeletal muscle is an attractive target tissue for gene therapy involving both muscle and nonmuscle disorders. HIV-1-based vectors transduce mature skeletal muscle; however, the use of these vectors for human gene therapy may be limited by biosafety concerns. In this study, we investigated gene transfer using lentivirus vectors based on the equine infectious anemia virus (EIAV) in skeletal muscle in vitro and in vivo. EIAV vectors transduce proliferating and differentiating C2C12 mouse muscle cells; furthermore, the addition of the woodchuck hepatitis posttranscriptional element to EIAV vectors markedly increases gene expression in these cells. A single injection of EIAV vectors into skeletal muscle of adult mice led to detectable gene marking and gene expression for the duration of the 3-month study. Use of a second-generation EIAV self-inactivating vector (E-SIN) increased transduction in muscle cells in vitro, and injection of E-SIN vectors into skeletal muscle resulted in increased gene marking and gene expression compared to first-generation EIAV vectors.


PLOS ONE | 2011

Dramatic Repositioning of c-Myb to Different Promoters during the Cell Cycle Observed by Combining Cell Sorting with Chromatin Immunoprecipitation

Anita M. Quintana; Ye E. Zhou; Janeth J. Pena; John P. O'Rourke; Scott A. Ness

The c-Myb transcription factor is a critical regulator of proliferation and stem cell differentiation, and mutated alleles of c-Myb are oncogenic, but little is known about changes in c-Myb activity during the cell cycle. To map the association of c-Myb with specific target genes during the cell cycle, we developed a novel Fix-Sort-ChIP approach, in which asynchronously growing cells were fixed with formaldehyde, stained with Hoechst 33342 and separated into different cell cycle fractions by flow sorting, then processed for chromatin immunoprecipitation (ChIP) assays. We found that c-Myb actively repositions, binding to some genes only in specific cell cycle phases. In addition, the specificity of c-Myb is dramatically different in small subpopulations of cells, for example cells in the G2/M phase of the cell cycle, than in the bulk population. The repositioning of c-Myb during the cell cycle is not due to changes in its expression and also occurs with ectopically expressed, epitope-tagged versions of c-Myb. The repositioning occurs in established cell lines, in primary human CD34+ hematopoietic progenitors and in primary human acute myeloid leukemia cells. The combination of fixation, sorting and ChIP analysis sheds new light on the dynamic nature of gene regulation during the cell cycle and provides a new type of tool for the analysis of gene regulation in small subsets of cells, such as cells in a specific phase of the cell cycle.


Journal of Medical Virology | 2000

Repression of tax-mediated human t-lymphotropic virus type 1 transcription by inducible cAMP early repressor (ICER) protein in peripheral blood mononuclear Cells

Garret C. Newbound; John P. O'Rourke; Nathaniel D. Collins; Janice M. Andrews; James W. DeWille; Michael D. Lairmore

Human T‐lymphotropic virus type 1 (HTLV‐1) infection causes adult T‐cell leukemia and is characterized by long periods of clinical latency with low levels of viral production. Transcription of HTLV‐1 is controlled through sequences in the promoter and enhancer regions of the long terminal repeat of the integrated provirus. Important among these sequences are three 21 bp imperfect repeats responsive to the viral oncogenic protein Tax (TRE). Members of the CREB/ATF‐1/CREM family of transcription factors bind to TRE‐1 and are critical for HTLV‐1 transcription. Other less studied family members include the inducible cAMP early repressor (ICER) proteins. ICER proteins lack phosphorylation and activation domains and are potent inhibitors of transcription. The ability of ICER to bind TRE‐1 and its effects on HTLV‐1 Tax mediated transcription have not been studied in the natural cell targets of the virus, peripheral blood mononuclear cells (PBMC). We show that ICER mRNA levels are low in quiescent PBMC, but rise and remain elevated for up to 18 hr after mitogenic stimulation of these cells. Electrophoretic mobility shift assays using recombinant Tax and ICER demonstrate that ICER binds TRE‐1 and that binding is increased in the presence of Tax. Furthermore, over expression of ICER IIγ suppressed Tax‐mediated transcription whereas an anti‐sense ICER II plasmid designed to block endogenous ICER enhanced Tax‐mediated transcription in activated PBMC. Together our data indicate that ICER inhibits Tax‐mediated transcription in activated PBMC and suggest a role for ICER in maintenance of HTLV‐1 persistence. J. Med. Virol. 62:286–292, 2000.


Gene Therapy | 2005

Optimization of equine infectious anemia derived vectors for hematopoietic cell lineage gene transfer

John P. O'Rourke; John C. Olsen; Bruce A. Bunnell

Gene transfer into hematopoietic cells may allow correction of a variety of hematopoietic and metabolic disorders. Optimized HIV-1 based lentiviral vectors have been developed for improved gene transfer and transgene expression into hematopoietic cells. However, the use of HIV-1 based vectors for human gene therapy may be limited due to ethical and biosafety issues. We report that vectors based on the non-primate equine infectious anemia virus (EIAV) transduce a variety of human hematopoietic cell lines and primary blood cells. To investigate optimization of gene expression in hematopoietic cells, we compared a variety of post-transcriptional elements and promoters in the context of EIAV vectors. We observed cell specific increase in the number of transgene expressing cells with the different post-transcriptional elements, whereas the use of elongation factor alpha 1 (EFα1) promoter resulted in significant increases in both the number of transgene expressing cells and the level of transgene protein in all cell types tested. We then demonstrate increased transduction of hematopoietic cells using a second-generation EIAV vector containing a self-inactivating EIAV LTR and the EIAV central polypurine tract (cppt). These data suggest that optimized EIAV vectors may be a suitable alternative to HIV-1 vectors for use in hematopoietic gene therapy.

Collaboration


Dive into the John P. O'Rourke's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Scott A. Ness

University of New Mexico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John C. Olsen

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anita M. Quintana

St. Jude Children's Research Hospital

View shared research outputs
Top Co-Authors

Avatar

Carole R. Baskin

Nationwide Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Donald B. Kohn

University of California

View shared research outputs
Researchain Logo
Decentralizing Knowledge